Remagine Labs Completes Series Seed Financing

Remagine Labs has completed its Series Seed preferred stock financing, with participation from existing investors Monash Investment Holdings and Innovation Victoria alongside lead investor Praxis Precision Medicines. This closing supports continued development of our wearable iontophoretic transdermal drug delivery platform. We're grateful for the continued confidence of our investor group as we advance toward first-in-human studies.